

Method validation to assess in vivo cellular and subcellular changes in
buccal mucosa cells and saliva following CBCT examination

Peer-reviewed author version

BELMANS, Niels; Gilles, Liese; Virag, Piroska; Hedesiu, Mihaela; Salmon, Benjamin;
Baatout, Sarah; Lucas, Stéphane; Jacobs, Reinhilde; LAMBRICHTS, Ivo &
MOREELS, Marjan (2019) Method validation to assess in vivo cellular and
subcellular changes in buccal mucosa cells and saliva following CBCT examination.
In: DENTOMAXILLOFACIAL RADIOLOGY, 48 (6).

DOI: 10.1259/dmfr.20180428

Handle: <http://hdl.handle.net/1942/28106>

1 **Title**

2 Method validation to assess in vivo cellular and subcellular changes in buccal mucosa cells and saliva
3 following CBCT examinations

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

Abstract

Objectives

Cone-beam computed tomography (CBCT) is a medical imaging technique used in dental medicine. However, there are no conclusive data available indicating that exposure to X-ray doses used by CBCT are harmless. We aim, for the first time, to characterize the potential age-dependent cellular and subcellular effects related to exposure to CBCT imaging. Current objective is to describe and validate the protocol for characterization of cellular and subcellular changes after diagnostic CBCT.

Methods

Development and validation of a dedicated two-part protocol: 1) assessing DNA double strand breaks (DSBs) in buccal mucosal (BM) cells and 2) oxidative stress measurements in saliva samples. BM cells and saliva samples are collected prior to and 0.5 hours after CBCT examination. BM cells are also collected 24 hours after CBCT examination. DNA DSBs are monitored in BM cells via immunocytochemical staining for γ H2AX and 53BP1. 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG) and total antioxidant capacity are measured in saliva to assess oxidative damage.

Results

Validation experiments show that sufficient BM cells are collected ($97.1\% \pm 1.4\%$) and that γ H2AX/53BP1 foci can be detected before and after CBCT examination. Collection and analysis of saliva samples, either sham exposed or exposed to IR, show that changes in 8-oxo-dG and total antioxidant capacity can be detected in saliva samples after CBCT examination.

Conclusion

The DIMITRA Research Group presents a two-part protocol to analyze potential age-related biological differences following CBCT examinations. This protocol was validated for collecting BM cells and saliva and for analyzing these samples for DNA DSBs and oxidative stress markers, respectively.

Keywords

Dental Cone-Beam Computed Tomography – DNA Double Strand Breaks – Oxidative stress – Buccal mucosal cells - Saliva

Introduction

Dental cone-beam computed tomography (CBCT) is a relatively new and innovative diagnostic imaging technique introduced in oral health care at the turn of the century.^(1, 2) Its growing use lies in the diagnostic potential related to the transition from two-dimensional (2D) to three-dimensional (3D) dentomaxillofacial diagnostic imaging.⁽³⁻⁶⁾ CBCT uses a cone-shaped X-ray beam and a 2D detector to generate 3D images. Briefly, the source-detector rotates around the patient once, while generating a series of 2D images. These images are then reconstructed into a 3D volume data set using a specialized algorithm.^(3, 7-9) Specifically designed to produce cross-sectional images of the oral and maxillofacial region, combined with its low cost and easy accessibility, CBCT technology has rapidly evolved in the past decade. Nowadays it has become a widely available diagnostic tool for clinicians and has therefore found applications in multiple dental specialties, including implant planning, endodontics, orthodontics and maxillofacial surgery.^(1, 2, 4, 8, 10-12)

Like other medical imaging techniques, such as computed tomography (CT), CBCT uses X-rays for its image acquisition. However, ionizing radiation (IR) is capable of damaging biomolecules (e.g. DNA or proteins) directly or indirectly via the hydrolysis of water which generates free radicals, such as reactive oxygen species (ROS).^(13, 14) Although CBCT is defined as a low dose imaging technique by the European High-Level Expert Group on European Low Dose Risk Research (HLEG) (www.hleg.de), it is misleading to see it as a 'low-dose' imaging modality just because it only takes one rotation compared to multiple rotations in conventional CT. As in CT, the absorbed dose in CBCT heavily depends on selectable exposure parameters that determine the image quality such as kVp, mAs, field of view (FOV), amount of 2D projections, reconstitution algorithm, etc..^(4, 15-18) Therefore, a wide range of CBCT doses is observed, typically ranging from about 0.010 to 1.100 mSv per examination.^(15, 17-22) CBCT doses are lower than CT

doses (organ dose of about 15 mSv), however, they are higher than classical 2D dental radiography techniques (organ dose of 0.001 – 0.1 mSv).^(4, 16, 23-26)

More recently, the dose of ionizing radiation delivered to pediatric patients has become a major concern among clinicians worldwide.^(20, 24) In 2010, the New York Times was the first major newspaper to bring this concern to the attention of the general public when they published the article entitled “Radiation Worries for Children in Dentists’ Chairs”.⁽²⁷⁾ In practice, especially in orthodontics, a large portion of CBCT examinations is performed on children (< 18 years old), who are known to be more radiosensitive than adults.^(18, 28-30) These concerns about the dose, combined with an increasing amount of radiological examinations annually, have led to questions about the biological uncertainties associated with radiation-induced health risks at low doses in dental radiology.^(24, 31, 32)

Exposure to IR, such as X-rays, could result in damage to important biomolecules, either directly, but mostly indirectly via generation of free radicals, usually through hydrolysis of water. These radicals (e.g. reactive oxygen species (ROS)) can in turn damage biomolecules in nano- to microseconds.⁽¹⁴⁾ Since more than 60% of a cell consists of water, most of the DNA damage is caused indirectly via ROS (e.g. the hydroxyl radical, superoxide radicals and hydrogen peroxide).^(25, 33) An excess of ROS causes oxidative stress. In the context of oral pathology, oxidative stress is associated with periodontitis, dental caries and oral cancers.^(34, 35) ROS can cause oxidative DNA damage through oxidative base lesions, of which over 20 different lesions have been identified.⁽³⁶⁾ An example hereof is 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a mutagenic base modification.⁽³⁷⁾ Other types of DNA lesions include single strand breaks, double strand breaks (DSBs) and base alterations.^(33, 38) DNA double strand breaks (DSBs) are the most critical DNA lesions caused by IR. When not repaired correctly, DSBs can lead to chromosome rearrangements, mutations and loss of genetic information.⁽³⁹⁻⁴⁴⁾ To protect themselves, eukaryotic cells have developed the DNA damage response (DDR), a set of signaling and DNA repair pathways.⁽⁴⁵⁻⁴⁷⁾

Human buccal mucosa (BM) cells are useful for determining exposure to several environmental factors.^(48, 49) Furthermore, BM cells are an easy accessible source of cells that can be sampled in a minimally invasive way.^(50, 51) As such, they are being increasingly used to investigate the effects of exposure to genotoxins that can cause DNA damage and cell death.^(48, 51, 52)

Another easy accessible biological sample is saliva, which, like BM cells, is easy to collect in an inexpensive, painless and non-invasive way.⁽⁵³⁾ Known as the 'mirror of the body', saliva is finding its way to research and the clinic as a diagnostic fluid.^(35, 54, 55) To date, the salivary metabolome has been described and saliva has been used to link oxidative stress markers to several oral diseases, such as dental caries and periodontitis.^(34, 35, 56)

Effective dose (ED), measured in mSv, is a dose quantity that takes following factors into account: 1) the absorbed dose to all organs of the body, 2) the relative harm of the type of radiation, and 3) the radiosensitivity of each organ. Although ED is an accepted term since its introduction in radiation protection, it is often criticized. For example the weighing factors used to calculate the ED are determined by scientific committees and may evolve over time.⁽⁵⁷⁻⁵⁹⁾ Furthermore, the ED is independent of gender and age at exposure, whereas epidemiological data indicate that both gender and age at exposure are important parameters.⁽⁶⁰⁾

A European project funded by the Open Project for European Radiation Research Area (OPERRA) denoted as DIMITRA (Dentomaxillofacial Paediatric Imaging: An Investigation Towards Low Dose Radiation Induced Risks) was initiated in order to characterize any potential cellular and subcellular effects induced by dental CBCT imaging, with a focus on age- and gender specificity and with reference to simulated ED (www.dimitra.be). *In vitro* results from DIMITRA were published previously, showing transient increases in DNA DSBs and changes in inflammatory cytokines after CBCT exposure of dental stem cells *in vitro*.⁽⁶¹⁾ The objective of the present report is to describe and validate a two-part protocol enabling the DIMITRA project to assess the potential age-related cellular and subcellular effects using DNA DSB detection in buccal mucosal cells and salivary oxidative stress measurement. To the best of our knowledge, a protocol and method validation for characterizing cellular and subcellular effects of CBCT exposure has not yet been described.

Materials and methods

Description of the DIMITRA protocol

Synthetic swabs (EpiCentre®, Madison, USA) are used to collect BM cells from eligible patients. Eligibility criteria are: having no systemic or acute diseases, taking no medication (antibiotics or anti-inflammatory drugs), having a good oral hygiene and giving informed consent prior to conclusion. When eligible, patients were asked to complete a questionnaire (supplementary data 1). At least one hour prior to BM cell collection, subjects are asked not to eat, brush their teeth or smoke. Just before BM cell collection, subjects rinse their mouth twice with water to remove excess debris. BM cells are collected from each patient just before, 0.5 hours after and 24 hours after CBCT examination (fig. 1), using a protocol modified from Thomas *et al.* (2009).⁽⁵⁰⁾ The 24 hours samples are collected at the patients' homes. To this end patients receive detailed instruction sheets (supplementary data 2). After collection, samples are sent to SCK•CEN via a professional courier service.

Buccal mucosal cell collection and fixation

Per patient six 15 ml conical tubes (Cellstar®, Greiner Bio-One, Vilvoorde, Belgium) (one for each time point and cheek side) containing 10 ml of Saccomanno's fixative (SF) (50% ethanol, 2% polyethylene glycol, 48% MilliQ water) are prepared. The swab is taken out of the package by the plastic handle. It is important not to touch the swab itself. Then the swab is placed against the middle of the patient's cheek. For reproducibility, the same cheek was used every time. Next, it is pressed firmly against the cheek and moved in an upward-downward motion while turning the swab for at least 30 seconds. The swab is then placed into SF in the 15 ml conical tube and shaken in such a manner that the cells are dislodged and released into SF. The tubes are then stored at 4°C (for up to 7 days) before shipment to SCK•CEN by courier service.

Within 7 days after sample collection, the BM cells are harvested from SF. For this purpose, the 15 ml conical tubes are centrifuged at 580g for 10 minutes at room temperature (RT). The supernatant is aspirated until about 1 ml is left. 5 ml of autoclaved buccal buffer (BuBu) (0.01 M Tris-HCl, 0.1 M EDTA, 0.02 M NaCl, 1% FBS, pH = 7) is added to the tube, after which the cells are vortexed briefly. Then, the cells are centrifuged at 580g for 10 minutes at RT. The supernatant is removed completely and the cells are washed with 5 ml BuBu and centrifuged at 580g for 10 minutes at RT. This washing step is repeated

twice to inactivate DNAses from the oral cavity and to remove excess debris and bacteria. After washing, the supernatant is removed and the cells are resuspended in 5 ml of BuBu and vortexed briefly. Next, the BM cells are passed through a 100 µm nylon filter (Falcon®, VWR Belgium, Leuven, Belgium) into a 50 ml conical tube (Cellstar®, Greiner Bio-One, Vilvoorde, Belgium) to remove large aggregates of unseparated cells. The 50 ml conical tube holding the filter is then centrifuged at 580g for 10 minutes at RT. Afterwards, the BM cells in the filtrate are transferred to a new 15 ml conical tube. Then the BM cells are centrifuged one last time at 580g for 5 minutes at RT. The supernatant is removed and the BM cells are resuspended in 1 ml of BuBu. The BM cells are then centrifuged at 580g for 5 minutes at RT and the supernatant is discarded afterwards. Then, the BM cells are fixed in 500 µl of 2% paraformaldehyde (PFA) (Sigma Aldrich, St-Louis, MO, USA) while vortexing the BM cells and adding the PFA dropwise. The BM cells are incubated for at least 15 minutes at RT. After incubation, the BM cells are centrifuged at 580g for 5 minutes. The supernatant is discarded and the BM cells are washed twice using 1x phosphate-buffered saline (PBS) (Gibco, Life Technologies, Ghent, Belgium). After the last washing step, the BM cells are resuspended in 1 ml 1x PBS. The BM cells can now be stored at 4°C for a longer period or used immediately for immunocytochemical staining.

Immunocytological staining for DNA double strand breaks: γH2AX and 53BP1 staining

Before immunocytochemical staining, the BM cells need to be transferred from the 15 ml conical tubes to coverslips by cytocentrifugation. The BM cells are washed using 200 µl of 1x PBS twice. During washing, poly-L-lysine coated coverslips, which assure good attachment of the BM cells, are placed on a microscope slide which is then inserted in a cytofunnel (ThermoFisher, Waltham, MA, USA). Next, 100 µl of cell suspension is pipetted into each sample cup of a Cytofunnel. The cytofunnels are centrifuged at 1200 rpm for 10 minutes in a cytocentrifuge (ThermoFisher, Waltham, MA, USA) at RT, causing the BM cells to adhere to the coverslip inside the cytofunnel. After centrifugation, the coverslips are removed and placed into a 4-well culture plate (Nunc, ThermoFisher Scientific, Roskilde, Denmark) so the BM cells are facing up. The BM cells are allowed to air-dry for 2 minutes at RT.

Immunocytochemical staining was performed using a protocol as previously described by our group.⁽⁶²⁻

⁶⁴⁾ First the BM cells are washed twice using cold 1x PBS for 5 minutes on a rocking platform. After washing, the BM cells are permeabilized for 3 minutes using 0.25% Triton X-100 in 1x PBS at RT. Next, the BM cells are washed three times with 1x PBS. Then the BM cells are blocked with 1x pre-immunized goat serum (ThermoFisher Scientific, Waltham, MA USA) in a solution of 1x TBST, 0.005 g/v% TSA blocking powder (PerkinElmer, FP1012, Zaventem, Belgium) (TNB) for 1 hour at RT. After blocking the primary mouse monoclonal anti- γ H2AX antibody (Millipore 05-636, Merck, Overijse, Belgium) (1:300 in TNB) and rabbit polyclonal anti-53BP1 antibody (Novus Biologicals NB100-304, Abingdon, UK) (1:1000 in TNB) are added. Next, the BM cells are incubated overnight at 4°C on a rocking platform. After incubation, the BM cells are washed three times with 1x PBS. Then the secondary goat anti-mouse Alexa Fluor® 488-labeled antibody (1:300 in TNB) and goat anti-rabbit Alexa Fluor® 568-labeled antibody (1:1000 in TNB) (ThermoFisher Scientific, A11001, Waltham, MA USA) were added. The BM cells are incubated for 1 hour on a rocking platform in the dark. Afterwards, the BM cells are washed twice using 1x PBS. Next, slides are mounted with ProLong Diamond antifade medium with 4',6-diamidino-2-phenylindole (DAPI) (ThermoFisher Scientific, Waltham, MA USA).

Finally, images are acquired with a Nikon Eclipse Ti fluorescence microscope using a 40× dry objective (Nikon, Tokyo, Japan). Images are analyzed using open source Fiji software.⁽⁶⁵⁾ The software allows to analyze each nucleus based on the DAPI signal. Within each nucleus, the intensity signals from the Alexa 488 and Alexa 568 fluorochromes are analyzed after which the number of co-localized γ H2AX and 53BP1 foci per nucleus are determined in an automated manner using the Cellblocks toolbox (fig. 2).⁽⁶⁶⁾

Saliva collection and analysis

Saliva samples are collected right before and 0.5 hours after CBCT examination (fig. 1) using the passive drool method, which is considered to be the 'gold standard' for saliva sampling.⁽⁶⁷⁾ As with the BM cells (saliva is sampled at the same time), subjects are asked not to eat, brush their teeth or smoke one hour prior to saliva sampling. Just before saliva collection, subjects will rinse their mouth twice with water to remove excess debris. If blood is detected in the saliva, the sample is not included for this study. The

saliva samples will be stored at -20°C immediately after collection before shipment to SCK•CEN by courier service. Once at SCK•CEN samples will be centrifuged at 10 000g at 4°C to remove most of the mucus and the supernatant will be stored at -80°C. The stored samples will be used to determine 8-oxo-dG concentrations and the total antioxidant capacity (fig. 2).

8-oxo-dG determination

8-oxo-dG concentrations will be determined by competitive enzyme-linked immunosorbent assay (ELISA) (Health Biomarkers Sweden AB, Stockholm, Sweden). To remove substances other than 8-oxo-dG which could cross-react with the monoclonal antibody used in the ELISA-kit, 800 µL sample will be purified prior to ELISA using a C18 solid phase extraction column (Varian, Lake Forest, CA, USA) after which the samples are freeze-dried. This purification is performed twice.⁽⁶⁸⁾

The 8-oxo-dG concentration of saliva will be measured based on a modified ELISA protocol provided by Health Biomarkers Sweden AB (Stockholm, Sweden). The protocol will be performed as previously described by Haghdoost *et al.*⁽⁶⁹⁾ Briefly, 270 µL of purified sample/standard will be mixed with 165 µL of primary antibody (80 ng/mL) mix in Eppendorf tubes. Next the samples will be incubated for 2 hours at 37°C. During incubation, the ELISA plate will be washed twice using 1x PBS. After incubation 140 µL of sample/standard will be loaded onto the plate in triplicate. The plate will be incubated overnight at 4°C on a horizontal shaker. Next the plate will be washed three times using 1x washing solution. After washing 140 µL of secondary antibody mix is added to each well. The plate is incubated for 2 hours at RT on a horizontal shaker. Next the plate is washed three times with 1x washing solution and once more with 1x PBS. Finally, the reaction is visualized by the addition of 140 µL chromogenic substrate 3,3',5,5'-Tetramethylbenzidine (One-Step substrate system; Dako, Glostrup Municipality, Denmark), and further incubation in the dark for 15 minutes. The reaction is stopped by adding 70 µL of 2M H₂SO₄. The absorbance is measured at 450 nm (signal) and 570 nm (background) using a microplate reader (ClarioStar, BMG Labtech, Ortenberg, Germany) (fig. 2).

Total antioxidant capacity

To determine the antioxidant capacity of saliva samples, the ferric reducing antioxidant power (FRAP) assay is used (Cell Biolabs, CA, USA). The FRAP assay will be performed according to the manufacturer's instructions. Briefly, per well of a 96-well plate 100 µl of sample/standard and 100 µl of reaction reagent are added. Next the samples/standards are incubated for 10 minutes at RT on a horizontal shaker. Finally, the absorbance will be measured at 560 nm using a microplate reader (ClarioStar, BMG Labtech, Ortenberg, Germany). The results will be expressed as Iron(II) concentration (µM) or FRAP value (fig. 2).

Protocol validation

Pilot study population

Healthy adults (N = 6) are included in this pilot study to validate the DIMITRA study protocol. These patients are referred for a CBCT examination. All patients were asked to sign informed consent forms prior to being included in the study. The validation study was approved by the ethical committees of the participating hospitals, since this is part of the scope of the DIMITRA study.

Flow cytometrical identification of buccal mucosal cells

Cells collected using the method described earlier are identified with the epithelial cell marker cytokeratin 4 (CK4) and lymphoid cell marker CD45 to identify the amount of BM cells collected with the swab. A431 and PC3 (courtesy of Katrien Konings) cell lines are used as a positive control for CK4 expression. Jurkat cells are used as a positive control for CD45 expression.

All cells are washed with 1xPBS and fixed in ice-cold (-20°C) 70% ethanol at a concentration of 1×10^6 cells/ml or 2×10^6 cells/ml (Jurkat). Next, cells are washed once with a solution of 1x PBS, 5% FBS (GIBCO, Life Technologies, Ghent, Belgium) and 0.25% Triton X-100 (Sigma-Aldrich chemistry, St-Louis, MO USA) (PFT) and are then blocked for 1h at RT in PFT. After blocking, cells are incubated with a rabbit anti-CK4 antibody (diluted 1:100 in PFT) overnight at 4°C on a horizontal shaker. Next, cells are washed twice with PFT. Subsequently, Alexa 488-conjugated donkey anti-rabbit secondary antibody (diluted 1:200 in PFT) and primary mouse anti-human CD45 antibody labelled with allophycocyanin (diluted 1:50 in PFT) are added and the cells were incubated for 2h at RT in the dark. After incubation, the cells are washed twice

with PFT and treated with 10 µg/ml of the DNA dye 7-AminoActinomycin D (7-AAD) for 15 min at RT. 7-AAD is used to distinguish cellular material from debris. Furthermore, it gives information about the current cell cycle phase of the samples. Finally, the samples are filtered on a BD conical tube (Falcon®, Corning, NY, USA) and analyzed on the BD Accuri™ C6 Flow Cytometer (BD Biosciences, San Jose, CA USA). At least 10.000 events are measured. Single-colour stained cells are included for colour compensation. Gating is based on using A431, PC3 and Jurkat cells as positive/negative control for CK4 or CD45. Cells in G₁/G₀ phase and CK4⁺ are identified as BM cells.

Histological staining for epithelial cell identification

Cells are collected using the method described earlier and were stained using Giemsa to allow for histological examination of the cells collected in the swab. After the cells are fixed in 2% PFA, they are spotted on poly-L-lysine coated coverslips (see above). Next, the cells are stained with Giemsa (1:50 in 0.2M acetate buffer, pH = 3.36) (VWR International, Radnor, PA, USA) for 1 hour at RT. After incubation, the cells are washed twice with milliQ water. Next, the slides are mounted with DPX (VWR International, Radnor, PA, USA). Finally, images are acquired with a Nikon Eclipse Ti microscope using a 20× dry objective for brightfield image acquisition (Nikon, Tokyo, Japan).

Statistics

Statistical analyses is performed using GraphPad Prism 7.02 (GraphPad Inc., CA, USA). Induction of DNA DSBs in BM cells is analyzed using repeated measures ANOVA. Both 8-oxo-dG concentrations and FRAP values before and after CBCT are compared using a paired t-test. To perform the above listed parametric tests, values should be normally distributed and the variances should be equal. Should these conditions not be met, non-parametric alternatives are used. P values lower than 0.05 are considered as statistically significant. Age-related effects are not considered during the validation experiment.

Results

Validation of the described protocol was performed on samples collected from adults (Table 1). BM cells were collected from adult volunteers (n = 6) using buccal swabs. Characterization of the cells collected by the swabs was performed using flow cytometrical and light microscopical analysis. CK4⁺ cells (that were in G₁/G₀ phase) were identified as BM cells. Flow cytometrical analysis showed that 97.1% ± 1.4% of the cells were CK4⁺ BM cells, whereas less than 1% of cells were CD45⁺. These CD45⁺ cells are most likely leukocytes (fig. 3). Further histological analysis confirmed that the collected cells are indeed BM cells, in various stages of exfoliation: some are nucleated, while others are not (fig. 4A, arrowheads).

The presence of DNA DSBs in BM cells was detected using an immunocytochemical staining for γH2AX and 53BP1 (fig. 4B-E). Analysis of colocalized γH2AX and 53BP1 foci shows that 0.015 ± 0.012 foci/nuclei were counted before CBCT and 0.028 ± 0.028 foci/nuclei were counted after (p = 0.99).

Saliva samples were collected from adults that were subjected to CBCT examination twice: once without IR exposure (sham control = group 1) and once with IR exposure (= group 2). These samples (n = 5) were used to validate the protocols for the 8-oxo-dG and FRAP determination.

The change in 8-oxo-dG levels before and after CBCT exposure between group 1 and group 2 was compared. Group 1 showed no difference (-0.09 ± 0.44 ng/ml; p = 0.88) in 8-oxo-dG levels whereas an increasing trend was found in group 2 (2.5 ± 3.0 ng/ml; p = 0.19). Comparison of the changes in both groups was not significant (p = 0.15), but it shows that after IR exposure (due to CBCT examination) changes in 8-oxo-dG levels can be detected.

In combination with the 8-oxo-dG ELISA, a FRAP assay was performed. When comparing FRAP values before and after CBCT examination, results show that the FRAP value does not change in group 1 (-3.6 ± 69; p > 0.99), but there is a decreasing trend in group 2 (-18 ± 49; p = 0.31). The change between both groups does not differ significantly (p = 0.89), but these data show that after IR exposure (due to CBCT examination) changes in FRAP values can be detected.

Discussion

Currently, the main challenge in the field of radiation protection is identifying biomarkers that allow detection of cellular and subcellular changes due to exposure to low doses of IR (< 0.1 Gy). These

biomarkers could then be used to predict low dose IR-associated risks. To this end, blood is the most commonly used sample to study cellular and subcellular changes in the low dose range, such as the doses used in medical diagnostic imaging. Blood contains numerous cells that can be used for a variety of assays used in low dose radiation research, such as the micronucleus assay, dicentric assay, comet assay, γ H2AX assay, oxidative stress tests (e.g. 8-oxo-dG) and even gene expression assays.⁽⁷⁰⁻⁷⁶⁾ The advantage of blood sampling is that a standardized protocol can be used, the procedure is easy and small volumes suffice for most tests performed. However, the major limitation of drawing blood is that the procedure is invasive, which can cause discomfort to the patient, especially to pediatric patients.⁽⁷⁰⁾ The DIMITRA Research Group provides a two-part protocol to assess potential cellular and subcellular effects after exposure to low doses of IR, i.e. CBCT examinations. This protocol focusses on non-invasive samples, i.e. BM cells and saliva samples. Compared to blood samples, BM cells and saliva samples have several major advantages: collection is non-invasive, cheap, painless and therefore allows easy repeated sampling.^(50, 51, 53) This opens new opportunities for use in (oral) healthcare with an increased suitability when pediatric patients are involved. The two-part protocol focusses on detection of DNA DSBs and oxidative stress markers. Oxidative stress can induce oxidative DNA damage which has mutagenic and tumorigenic potential.⁽⁷⁷⁾ DNA DSBs, which can (partly) be caused by oxidative stress, is associated with carcinogenesis, an important health risk related to IR exposure.^(78, 79) Therefore, DNA DSB formation and repair are important markers to assess potential health risks in patients exposed to IR.

The current paper describes and validates this two-part protocol. The collection method for BM cells was validated by flow cytometry (presence of G₁/G₀ phase CK4⁺ cells) and light microscopy (Giemsa staining). BM cells from different mucosal layers were collected, although the majority of the cells were nucleated. These results show that this collection method yields sufficient BM cells for microscopical analysis. The use of γ H2AX foci in BM cells is described before as is the use of a γ H2AX/53BP1 immunofluorescent staining for the detection of DNA DSBs. ^(51, 64, 80-82) However, to the best of our knowledge, this is the first time that a protocol is proposed to detect DNA DSBs after CBCT examination, although other genotoxicity markers have been published before.⁽⁸³⁾ Our validation data show that that *ex vivo* BM cells can be used to perform γ H2AX/53BP1 analysis. Future studies will investigate whether age-dependent

differences can be detected in the amount of DNA DSBs after CBCT examination. For saliva collection, a protocol was described based on the passive drool method, after which the samples are immediately stored at -20°C. Comparison between sham exposure and IR exposure, i.e. CBCT examination, shows that changes in 8-oxo-dG and FRAP levels can be detected in saliva samples after CBCT examination. These findings confirm that the methods described in this paper are suited for evaluating potential effects of low dose IR exposure in BM cells and saliva samples. The changes detected here are small, but can be attributed to the age of the volunteers: adults are more radioresistant than children, therefore we hypothesize that the effects of low dose IR exposure might be greater in children.

Despite the aforementioned advantages and validation of the DIMITRA study protocol, some precautions should be taken into account when using BM cells and saliva. BM consists of several layers of cells, thus sampling should be done in an uniformed way to avoid differences in cell type distribution. For example, it is known that the amount of basal cells increases when the cheek is sampled repeatedly.^(48, 50) Therefore, the authors suggest to collect some test samples prior to the actual study and to characterize the cells that are collected, as described earlier. Although cigarette/cigar smoke is a known cytotoxin and genotoxin to BM cells⁽⁸⁴⁾, one limitation of this validation protocol is that 'smoking' was not included in the exclusion criteria. Therefore, it is recommended to add 'smoking' as an exclusion criterion when conducting studies in which BM cells are collected for this type of study.

Saliva composition can be affected by several factors, such as the collection itself, time of day, intake of antioxidants, time since tooth-brushing, presence of blood, drug intake, etc.. Moreover, some (pediatric) patients might not be able to produce (enough) saliva spontaneously. However, the authors recommend to not induce salivation actively, since this will create a bias when compared with spontaneous salivation.⁽³⁵⁾ To keep this type of bias to a minimum, our protocol is based on the passive drooling method to collect saliva, which is regarded as the gold standard.⁽⁶⁷⁾ Additional information from the patients on drug intake, previous radiation exposure, etc. should be obtained as well through a questionnaire.

For the post-imaging assessment, 30 minutes and 24 hours were chosen for γ H2AX/53BP1 staining based on previous results from SCK•CEN, in which the peak response is seen after 30 to 60 minutes and

most DNA damage is resolved after 24 hours.⁽⁶²⁻⁶⁴⁾ For the 8-oxo-dG analysis and FRAP assay, we chose time points based on Haghdoost *et al.*, who tested 8-oxo-dG after 30 minutes.⁽⁶⁹⁾ This coincides with BM cell sampling, which is an advantage since this way DNA DSB and 8-oxo-dG levels can be correlated. The results show that changes, especially in oxidative stress markers, can be detected at this time. However, it is possible that the selected time points are not the most optimal ones. Finally, we are not certain that the described methods for detecting DNA damage will be sensitive enough to detect changes following CBCT examination in children, since to the best of the authors' knowledge, this type of study has not been performed before. Current time points are selected based on literature, as mentioned above, but also out of practical consideration: i.e. not letting the patient wait too long after the CBCT examination. If necessary, and if patients are willing, it may be possible to include additional time points (e.g. 60 minutes after CBCT examination).

The DIMITRA study protocol presented here is designed to be cost effective, quick, painless and non-invasive. The use of this protocol, however, is not limited to this study and can be easily implemented in other (radio)biological studies. For example, this protocol can be used in a similar setting in which patients are exposed to a head and neck CT, or in cancer patients treated for head and neck cancer. Furthermore, the use of saliva can be used to monitor patients exposed to short- and long-lived radionuclides for diagnostics/therapy. These examples expand the use of this protocol from risk assessment in medical diagnostics, to follow-up/monitoring of radiotherapy patients, two distinctive field in medicine using ionizing radiation.

Conclusion

It is well-known that children are more radiosensitive than adults. Together with the increasing amount of radiological examinations annually, this has recently led to societal concerns about exposure to IR during medical procedures. The DIMITRA Research Group presents a dedicated, two-part protocol to analyze potential age-related biological differences in response to CBCT examinations in both pediatric and adult patients. This protocol was validated for collecting BM cells and saliva, as well as for analyzing BM cells and saliva samples for DNA damage and oxidative stress markers, respectively. After validation

in this paper, this dedicated protocol can be used in different age categories to detect potential cellular and subcellular effects following dental CBCT imaging.

Acknowledgements

The DIMITRA Research Group that contributed to this paper consists of N. Belmans, M. Moreels, S. Baatout, B. Salmon, A.C. Oenning, C. Chaussain, C. Lefevre, M. Hedesiu, P. Virag, M. Baciut, M. Marcu, O. Almasan, R. Roman, I. Barbur, C. Dinu, H. Rotaru, L. Hurubeanu, V. Istouan, O. Lucaciu, D. Leucuta, B. Crisan, L. Bogdan, C. Candea, S. Bran, G. Baciut, R. Jacobs, H. Bosmans, R. Bogaerts, C. Politis, A. Stratis, R. Pauwels, K. de F. Vasconcelos, L. Nicolielo, G. Zhang, E. Tijskens, M. Vranckx, A. Ockerman, E. Claerhout, E. Embrechts.

Figures




Figure 1. Flow chart for patient inclusion and patient sampling. *CBCT* = *Cone Beam Computed Tomography*; *BM* = *Buccal mucosa*




Figure 2. Flow chart for sample analysis. Schematic view of DNA double strand break detection in buccal mucosal cells and oxidative stress measurements in saliva samples. *DSB* = *Double-strand break*; *BM* = *Buccal mucosa*; *γH2AX* = *phosphorylated histone 2AX on Ser139*; *53BP1* = *p53-binding protein 1*; *8-oxo-dG* = *8-oxo-7,8-dihydro-2'-deoxyguanosine*; *FRAP* = *Ferric Reducing Antioxidant Power*; *ELISA* = *Enzyme-linked Immunosorbent assay*





Figure 3. Flow cytometrical identification of cells collected by buccal swab. **A.** Overview of the cells that were in G_1/G_0 phase. Note that no S or G_2/M phase were observed, indicating that the cells are fully differentiated cells. **B.** Over 97% of the cells collected by buccal swab are CK4⁺ epithelial cells (= buccal cells), whereas less than 1% are CD45⁺, indicating that cells of hematological lineage are present (N = 6).

420



421

422

423

424

425

426

427

428

Figure 4. Microscopical identification of cells collected by buccal swab. **A.** Giemsa stain clearly shows nucleated epithelial cells (arrowheads), as well as unnucleated cells. This indicates that cells from all mucosal layers are collected. Enough nucleated cells are collected to perform immunocytochemistry. **B-E.** Buccal cells with DNA double strand break identified by colocalization of γ H2AX and 53BP1. **B.** Buccal cell nucleus, DAPI stain. **C.** γ H2AX-positive focus. **D.** 53BP1-positive focus. **E.** Merged image of B, D and E.

Tables

Table 1. Overview of scan parameters per patient included in this validation study.

Patient	Age	Sex	Device	Field of view	mAs	kV	Acquisition time (seconds)
1	57	Female	Newtom VGi evo	10x5	11	110	5
2	41	Female	Newtom VGi evo	10x5	6	110	5
3	30	Female	Newtom VGi evo	10x10	8	110	5
4	30	Male	Newtom VGi evo	10x10	10	110	5
5	71	Male	Newtom VGi evo	10x10	8	110	5
6	27	Female	Newtom VGi evo	10x10	8	110	5

mAs = milliamperage; kV = kilovoltage

429

Supplementary data

431 *Supplementary data 1*

432 Extension: PDF file.

433 Title: Patient questionnaire.

Description: Example of questionnaire that needs to be completed by the patient or the parents of the patients upon entering the DIMITRA study. Data collected this way will be used to do analysis of age-, gender-related effects.

Supplementary data 2

Extension: PDF file.

Title: Patient instructions

Description: Example of the instruction sheet handed to the patients during the informed consent procedure.

References

1. Arai Y, Tammisalo E, Iwai K, Hashimoto K, Shinoda K. Development of a compact computed tomographic apparatus for dental use. *Dentomaxillofac Radiol.* 1999;28(4):245-8.
2. Mozzo P, Procacci C, Tacconi A, Martini PT, Andreis IA. A new volumetric CT machine for dental imaging based on the cone-beam technique: preliminary results. *European radiology.* 1998;8(9):1558-64.
3. Scarfe WC, Farman AG. What is cone-beam CT and how does it work? *Dent Clin North Am.* 2008;52(4):707-30, v.
4. Pauwels R. Cone beam CT for dental and maxillofacial imaging: dose matters. *Radiation protection dosimetry.* 2015;165(1-4):156-61.
5. Dawood A, Patel S, Brown J. Cone beam CT in dental practice. *British dental journal.* 2009;207(1):23-8.
6. Kapila SD, Nervina JM. CBCT in orthodontics: assessment of treatment outcomes and indications for its use. *Dentomaxillofac Radiol.* 2015;44(1):20140282.
7. Scarfe WC, Farman AG, Levin MD, Gane D, Scarfe WC, Farman AG, et al. Essentials of maxillofacial cone beam computed tomography - Clinical applications of cone-beam computed tomography in dental practice. *Alpha Omegan.* 2010;103(2):62-7.
8. De Vos W, Casselman J, Swennen GR. Cone-beam computerized tomography (CBCT) imaging of the oral and maxillofacial region: a systematic review of the literature. *Int J Oral Maxillofac Surg.* 2009;38(6):609-25.
9. Feldkamp LA, Davis LC, Kress JW. Practical Cone-Beam Algorithm. *J Opt Soc Am A.* 1984;1(6):612-9.
10. Suomalainen A, Pakbaznejad Esmaeili E, Robinson S. Dentomaxillofacial imaging with panoramic views and cone beam CT. *Insights Imaging.* 2015;6(1):1-16.
11. Shah N, Bansal N, Logani A. Recent advances in imaging technologies in dentistry. *World journal of radiology.* 2014;6(10):794-807.
12. Scarfe WC, Farman AG, Sukovic P. Clinical applications of cone-beam computed tomography in dental practice. *J Can Dent Assoc.* 2006;72(1):75-80.
13. UNSCEAR. SOURCES AND EFFECTS OF IONIZING RADIATION. 2000;Volume II: Effects.
14. the UNSCO, Radiation EoA. UNSCEAR 2013 Report: Sources, effects and risks of ionizing radiation. 2013;II Annex B - Effects of radiation exposure of children.
15. Ludlow JB, Davies-Ludlow LE, White SC. Patient risk related to common dental radiographic examinations: the impact of 2007 International Commission on Radiological Protection recommendations regarding dose calculation. *Journal of the American Dental Association (1939).* 2008;139(9):1237-43.
16. Pauwels R, Beinsberger J, Collaert B, Theodorakou C, Rogers J, Walker A, et al. Effective dose range for dental cone beam computed tomography scanners. *European journal of radiology.* 2012;81(2):267-71.
17. Oenning AC, Jacobs R, Pauwels R, Stratis A, Hedesiu M, Salmon B, et al. Cone-beam CT in paediatric dentistry: DIMITRA project position statement. *Pediatr Radiol.* 2017.
18. Marcu M, Hedesiu M, Salmon B, Pauwels R, Stratis A, Oenning ACC, et al. Estimation of the radiation dose for pediatric CBCT indications: a prospective study on ProMax3D. *Int J Paediatr Dent.* 2018.
19. Signorelli L, Patcas R, Peltomaki T, Schatzle M. Radiation dose of cone-beam computed tomography compared to conventional radiographs in orthodontics. *Journal of orofacial orthopedics = Fortschritte der Kieferorthopadie : Organ/official journal Deutsche Gesellschaft fur Kieferorthopadie.* 2016;77(1):9-15.
20. Li G. Patient radiation dose and protection from cone-beam computed tomography. *Imaging Sci Dent.* 2013;43(2):63-9.
21. Loubele M, Bogaerts R, Van Dijk E, Pauwels R, Vanheusden S, Suetens P, et al. Comparison between effective radiation dose of CBCT and MSCT scanners for dentomaxillofacial applications. *European journal of radiology.* 2009;71(3):461-8.

22. Centre for Radiation CaEH. Guidance on the safe use of dental cone beam CT (computed tomography) equipment. Oxfordshire: Health Protection Agency; 2010.
23. Theodorakou C, Walker A, Horner K, Pauwels R, Bogaerts R, Jacobs R. Estimation of paediatric organ and effective doses from dental cone beam CT using anthropomorphic phantoms. *Br J Radiol.* 2012;85(1010):153-60.
24. Department of Public Health EaSDoHP-F, Women and Children's Health Cluster (FWC). Communicating radiation risks in paediatric imaging - Information to support healthcare discussions about benefit and risk. Switzerland: World Health Organization; 2016.
25. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med.* 2007;357(22):2277-84.
26. RadiologyInfo.org. Radiation Dose in X-ray and CT exams. Accessed on 2018-12-06. Available from: <https://www.radiologyinfo.org/en/pdf/safety-xray.pdf>.
27. Bogdanich W. CMJ. Radiation Worries for Children in Dentists' Chairs. *New York Times.* 2010.
28. Brenner DJ. Estimating cancer risks from pediatric CT: going from the qualitative to the quantitative. *Pediatr Radiol.* 2002;32(4):228-1; discussion 42-4.
29. Hall EJ. Lessons we have learned from our children: cancer risks from diagnostic radiology. *Pediatr Radiol.* 2002;32(10):700-6.
30. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *Lancet.* 2004;363(9406):345-51.
31. UNSCEAR. SOURCES AND EFFECTS OF IONIZING RADIATION: UNSCEAR 2008 Report. New York: United Nations; 2010.
32. Holmberg O, Czarwinski R, Mettler F. The importance and unique aspects of radiation protection in medicine. *European journal of radiology.* 2010;76(1):6-10.
33. D. K. Maurya TPAD. Role of Radioprotectors in the Inhibition of DNA Damage and Modulation of DNA Repair After Exposure to Gamma-Radiation. In: Chen CC, editor. *Selected Topics in DNA Repair: InTech.*; 2011.
34. Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. *Periodontol 2000.* 2007;43:160-232.
35. Tothova L, Kamodyova N, Cervenka T, Celec P. Salivary markers of oxidative stress in oral diseases. *Front Cell Infect Microbiol.* 2015;5:73.
36. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. *FASEB J.* 2003;17(10):1195-214.
37. Kasai H, Nishimura S. Hydroxylation of deoxy guanosine at the C-8 position by polyphenols and aminophenols in the presence of hydrogen peroxide and ferric ion. *Gan.* 1984;75(7):565-6.
38. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, et al. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. *Cell cycle (Georgetown, Tex).* 2010;9(4):662-9.
39. Dugle DL, Gillespie CJ, Chapman JD. DNA strand breaks, repair, and survival in x-irradiated mammalian cells. *Proc Natl Acad Sci U S A.* 1976;73(3):809-12.
40. Olive PL. The role of DNA single- and double-strand breaks in cell killing by ionizing radiation. *Radiat Res.* 1998;150(5 Suppl):S42-51.
41. Jackson SP. Sensing and repairing DNA double-strand breaks. *Carcinogenesis.* 2002;23(5):687-96.
42. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. *Nature.* 2000;405(6787):697-700.
43. Vamvakas S, Vock EH, Lutz WK. On the role of DNA double-strand breaks in toxicity and carcinogenesis. *Crit Rev Toxicol.* 1997;27(2):155-74.
44. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. *Nat Genet.* 2001;27(3):247-54.
45. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. *Nucleic Acids Res.* 2008;36(17):5678-94.
46. Riches LC, Lynch AM, Gooderham NJ. Early events in the mammalian response to DNA double-strand breaks. *Mutagenesis.* 2008;23(5):331-9.
47. Ciccio A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol Cell.* 2010;40(2):179-204.
48. Torres-Bugarin O, Zavala-Cerna MG, Nava A, Flores-Garcia A, Ramos-Ibarra ML. Potential uses, limitations, and basic procedures of micronuclei and nuclear abnormalities in buccal cells. *Dis Markers.* 2014;2014:956835.
49. Spivack SD, Hurteau GJ, Jain R, Kumar SV, Aldous KM, Gierthy JF, et al. Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. *Cancer Res.* 2004;64(18):6805-13.
50. Thomas P, Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, et al. Buccal micronucleus cytome assay. *Nat Protoc.* 2009;4(6):825-37.
51. Siddiqui MS, Francois M, Fenech MF, Leifert WR. gammaH2AX responses in human buccal cells exposed to ionizing radiation. *Cytometry A.* 2015;87(4):296-308.
52. Sarto F, Tomanin R, Giacomelli L, Iannini G, Cupiraggi AR. The micronucleus assay in human exfoliated cells of the nose and mouth: application to occupational exposures to chromic acid and ethylene oxide. *Mutat Res.* 1990;244(4):345-51.
53. Lee JM, Garon E, Wong DT. Salivary diagnostics. *Orthod Craniofac Res.* 2009;12(3):206-11.
54. Mandel ID. Salivary diagnosis: more than a lick and a promise. *Journal of the American Dental Association (1939).* 1993;124(1):85-7.
55. Miller SM. Saliva testing--a nontraditional diagnostic tool. *Clin Lab Sci.* 1994;7(1):39-44.
56. Dame ZT, Aziat F, Mandal R, Krishnamurthy R, Bouatra S, Borzouie S, et al. The human saliva metabolome. *Metabolomics.* 2015;11(6):1864-83.
57. ICRP. Recommendations of the ICRP. ICRP Publication 26. 1977(Ann. ICRP 1 (3)).

58. ICRP. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. 1991(Ann. ICRP 21 (1-3).
59. ICRP. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. 2007(Ann. ICRP 37 (2-4)).
60. Stratis A. Customized Monte Carlo Modelling for Paediatric Patient Dosimetry in Dental and Maxillofacial Cone Beam Computed Tomography Imaging [Doctoral Thesis]. Leuven University Press: KU Leuven; 2018.
61. Virag P, Hedesiu M, Soritau O, Perde-Schrepler M, Brie I, Pall E, et al. Low-dose radiations derived from cone-beam CT induce transient DNA damage and persistent inflammatory reactions in stem cells from deciduous teeth. *Dentomaxillofac Radiol.* 2018;20170462.
62. Suetens A, Konings K, Moreels M, Quintens R, Verslegers M, Soors E, et al. Higher Initial DNA Damage and Persistent Cell Cycle Arrest after Carbon Ion Irradiation Compared to X-irradiation in Prostate and Colon Cancer Cells. *Front Oncol.* 2016;6:87.
63. Ghardi M, Moreels M, Chatelain B, Chatelain C, Baatout S. Radiation-induced double strand breaks and subsequent apoptotic DNA fragmentation in human peripheral blood mononuclear cells. *Int J Mol Med.* 2012;29(5):769-80.
64. Baselet B, Belmans N, Coninx E, Lowe D, Janssen A, Michaux A, et al. Functional Gene Analysis Reveals Cell Cycle Changes and Inflammation in Endothelial Cells Irradiated with a Single X-ray Dose. *Front Pharmacol.* 2017;8:213.
65. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012;9(7):676-82.
66. De Vos WH, Van Neste L, Dieriks B, Joss GH, Van Oostveldt P. High content image cytometry in the context of subnuclear organization. *Cytometry A.* 2010;77(1):64-75.
67. Munro CL, Grap MJ, Jablonski R, Boyle A. Oral health measurement in nursing research: state of the science. *Biol Res Nurs.* 2006;8(1):35-42.
68. Shakeri Manesh S, Sangsuwan T, Pour Khavari A, Fotouhi A, Emami SN, Haghdoost S. MTH1, an 8-oxo-2'-deoxyguanosine triphosphatase, and MYH, a DNA glycosylase, cooperate to inhibit mutations induced by chronic exposure to oxidative stress of ionising radiation. *Mutagenesis.* 2017;32(3):389-96.
69. Haghdoost S, Czene S, Naslund I, Skog S, Harms-Ringdahl M. Extracellular 8-oxo-dG as a sensitive parameter for oxidative stress in vivo and in vitro. *Free Radic Res.* 2005;39(2):153-62.
70. Vandevoorde C, Gomolka M, Roessler U, Samaga D, Lindholm C, Fernet M, et al. EPI-CT: in vitro assessment of the applicability of the gamma-H2AX-foci assay as cellular biomarker for exposure in a multicentre study of children in diagnostic radiology. *Int J Radiat Biol.* 2015;91(8):653-63.
71. El-Saghire H, Thierens H, Monsieurs P, Michaux A, Vandevoorde C, Baatout S. Gene set enrichment analysis highlights different gene expression profiles in whole blood samples X-irradiated with low and high doses. *Int J Radiat Biol.* 2013;89(8):628-38.
72. Sudprasert W, Navasumrit P, Ruchirawat M. Effects of low-dose gamma radiation on DNA damage, chromosomal aberration and expression of repair genes in human blood cells. *Int J Hyg Environ Health.* 2006;209(6):503-11.
73. Ponzinibbio MV, Crudeli C, Peral-Garcia P, Seoane A. Low-dose radiation employed in diagnostic imaging causes genetic effects in cultured cells. *Acta Radiol.* 2010;51(9):1028-33.
74. Das Roy L, Giri S, Singh S, Giri A. Effects of radiation and vitamin C treatment on metronidazole genotoxicity in mice. *Mutat Res.* 2013;753(2):65-71.
75. Ainsbury EA, Al-Hafidh J, Bajinskas A, Barnard S, Barquinero JF, Beinke C, et al. Inter- and intra-laboratory comparison of a multibiodosimetric approach to triage in a simulated, large scale radiation emergency. *Int J Radiat Biol.* 2014;90(2):193-202.
76. Sangsuwan T, Haghdoost S. The nucleotide pool, a target for low-dose gamma-ray-induced oxidative stress. *Radiat Res.* 2008;170(6):776-83.
77. Tsuzuki T, Nakatsu Y, Nakabeppu Y. Significance of error-avoiding mechanisms for oxidative DNA damage in carcinogenesis. *Cancer Sci.* 2007;98(4):465-70.
78. Magnander K, Elmroth K. Biological consequences of formation and repair of complex DNA damage. *Cancer letters.* 2012;327(1-2):90-6.
79. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. *Mutat Res.* 2011;711(1-2):193-201.
80. Gonzalez JE, Roch-Lefevre SH, Mandina T, Garcia O, Roy L. Induction of gamma-H2AX foci in human exfoliated buccal cells after in vitro exposure to ionising radiation. *Int J Radiat Biol.* 2010;86(9):752-9.
81. Vandevoorde C, Vral A, Vandekerckhove B, Philippe J, Thierens H. Radiation Sensitivity of Human CD34(+) Cells Versus Peripheral Blood T Lymphocytes of Newborns and Adults: DNA Repair and Mutagenic Effects. *Radiat Res.* 2016;185(6):580-90.
82. Deminice R, Sicchieri T, Payao PO, Jordao AA. Blood and salivary oxidative stress biomarkers following an acute session of resistance exercise in humans. *Int J Sports Med.* 2010;31(9):599-603.
83. da Fonte JBM, de Andrade TM, Albuquerque RLC, de Melo MDB, Takeshita WM. Evidence of genotoxicity and cytotoxicity of X-rays in the oral mucosa epithelium of adults subjected to cone beam CT. *Dentomaxillofac Rad.* 2018;47(2).
84. de Geus JL, Wambier LM, Bortoluzzi MC, Loguercio AD, Kossatz S, Reis A. Does smoking habit increase the micronuclei frequency in the oral mucosa of adults compared to non-smokers? A systematic review and meta-analysis. *Clin Oral Investig.* 2018;22(1):81-91.